Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company specializing in engineered monoclonal antibodies and cytokines, has announced its participation in two investor conferences.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in the following upcoming investor conferences:

• Credit Suisse 30th Annual Healthcare Conference
  Presentation: Tuesday, November 9, 2:40 p.m. ET / 11:40 a.m. PT
  
  
• Jefferies London Healthcare Conference
  Presentation on-demand availability: Thursday, November 18, 8:00 a.m. GMT / 12:00 a.m. PT

Webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Replays will be archived on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb^® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006059/en/

Charles Liles
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Source: Xencor, Inc.